AZD-8835 - CAS 1620576-64-8
Catalog number:
1620576-64-8
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C22H31N9O3
Molecular Weight:
469.54
COA:
Inquire
Targets:
PI3K
Description:
AZD-8835 was selected as a clinical candidate for the treatment of PIK3CA-dependent cancers and is currently in phase I clinical trials. It is an orally bioavailable inhibitor of the class I (PI3K) catalytic subunit alpha (PIK3CA). IC50: PI3Kδ= 5.7 nM, PI
Publictions citing BOC Sciences Products
  • >> More
Appearance:
Light yellow to yellow Solid
Synonyms:
1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl]-1-ethyl-1,2,4-triazol-3-yl]piperidin-1-yl]-3-hydroxypropan-1-one AZD-8835 1620576-64-8 GTPL8915 SCHEMBL15877923 AZD8835 ZGRDYKFVDCFJCZ-UHFFFAOYSA-N BDBM185362 AZD 8835 AKOS027338670 compo
Solubility:
DMSO: ≥ 16 mg/mL
Storage:
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -33℃ for long term (months to years).
MSDS:
Inquire
Shelf Life:
2 years
Quantity:
Grams-Kilos
Boiling Point:
784.0±70.0 °C | Condition: Press: 760 Torr
Density:
1.45±0.1 g/cm3
InChIKey:
ZGRDYKFVDCFJCZ-UHFFFAOYSA-N
InChI:
1S/C22H31N9O3/c1-5-31-19(26-18(29-31)13-6-9-30(10-7-13)15(33)8-11-32)14-12-24-17(23)16(25-14)20-27-28-21(34-20)22(2,3)4/h12-13,32H,5-11H2,1-4H3,(H2,23,24)
Canonical SMILES:
CCN1C(=NC(=N1)C2CCN(CC2)C(=O)CCO)C3=CN=C(C(=N3)C4=NN=C(O4)C(C)(C)C)N
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PI3K Products


CAS 944396-07-0 BKM120

BKM120
(CAS: 944396-07-0)

BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...

CAS 1166227-08-2 A66

A66
(CAS: 1166227-08-2)

Inhibition of p110α alone by A66 treatment is sufficient to block insulin signalling to Akt/PKB in certain cell lines that harbor H1047R mutations in PIK3CA and...

CAS 870281-82-6 CAL-101 (GS-1101)

CAL-101 (GS-1101)
(CAS: 870281-82-6)

Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).

CAS 1218777-13-9 CAY10505

CAY10505
(CAS: 1218777-13-9)

CAY10505 is a phosphatidylinositol 3-kinase-γ inhibitor, was found to significantly improve acetylcholine-induced endothelium dependent relaxation, serum nitrat...

CAS 1202777-78-3 BKM120

BKM120
(CAS: 1202777-78-3)

BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...

PQR530
(CAS: 1927857-61-1)

PQR530 is a potent dual pan PI3K/mTOR inhibitor undergoing phase II clinical trials in 2016. Aberrant activation of the PI3K/mTOR signaling pathway promotes the...

TGR-1202 hydrochloride
(CAS: 1532533-78-0)

TGR-1202 hydrochloride is the hydrochloride salt of TGR-1202.TGR-1202, also known as RP5264, is a highly specific, orally available, PI3Kdelta inhibitor which i...

MLN1117
(CAS: 1268454-23-4)

MLN1117, also known as INK1117, is a PI3Kα inhibitor which could lead to the apoptosis and growth retardation of tumor cells expressed by PI3Kα. IC50: 15 nM.

CAS 1013098-90-2 PI3Kα/mTOR-IN-1

PI3Kα/mTOR-IN-1
(CAS: 1013098-90-2)

PI3Kα/mTOR-IN-1 is a potent dual inhibitor of PI3Kα/mTOR (Kis= 10.6 nM and 12.5 nM for mTOR and PI3Kα, respectively).

CAS 955977-50-1 PI-3065

PI-3065
(CAS: 955977-50-1)

PI-3065 is a novel potent and selective PI3K p110δ inhibitor with IC50 of 15 nM; exhibits > 100 fold selectivity against p110α, p110β, p110γ, DNA-PK and mTOR.

CAS 1383716-46-8 VPS34 inhibitor 1

VPS34 inhibitor 1
(CAS: 1383716-46-8)

VPS34 inhibitor 1 is a potent and selective inhibitor of VPS34 (IC50= 15 nM). Vps34 is a phosphoinositide 3-kinase (PI3K) class III isoform that has attracted m...

Duvelisib R enantiomer
(CAS: 1261590-48-0)

The R isomer analogue of Duvelisib which is a high selective PI3K δ/γ inhibitor.

CAS 5142-23-4 NSC 66389,3-MA

NSC 66389,3-MA
(CAS: 5142-23-4)

CAS 1276105-89-5 CNX-1351

CNX-1351
(CAS: 1276105-89-5)

CNX-1351 is a selective covalent Inhibitor of PI3Kα. In an end point assay, CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β, γ, an...

CAS 1431697-78-7 CAL-130 Hydrochloride

CAL-130 Hydrochloride
(CAS: 1431697-78-7)

In the absence of PTEN phosphatase tumor suppressor function, PI3Kγ or PI3Kδ alone can support leukemogenesis, whereas inactivation of both isoforms suppressed ...

RP-6530
(CAS: 1639417-53-0)

RP-6530, a purine derivative, has been found to be a PI3Kδ/γ inhibitor that could exhibit cytotoxicity in some lymphoma primary cells so that is significant in ...

CAS 1383716-33-3 VPS34-IN1

VPS34-IN1
(CAS: 1383716-33-3)

VPS34-IN1 is a potent and selective Vps34 inhibitor with potential anticancer activity. VPS34-IN1 inhibits Vps34 with 25 nM IC50 in vitro.

CAS 1349796-36-6 XL-765, SAR245409,

XL-765, SAR245409,
(CAS: 1349796-36-6)

CAS 1032568-63-0 Copanlisib

Copanlisib
(CAS: 1032568-63-0)

Copanlisib, also known as BAY 80-6946, is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BAY 80-6946 inhibits the activat...

GSK-2269557 HCl salt
(CAS: 1254036-77-5)

GSK-2269557 is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by GlaxoSmithKline. GSK-2269557 is highly selective for PI3Kδ over the close...

Quick Inquiry

Verification code

Featured Items